We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer (BAYRY) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Bayer (BAYRY - Free Report) closed at $16.36, marking a +0.46% move from the previous day. This move outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the drug and chemical company had lost 4.32% over the past month, lagging the Medical sector's loss of 2.82% and the S&P 500's loss of 0.19% in that time.
Investors will be hoping for strength from BAYRY as it approaches its next earnings release. On that day, BAYRY is projected to report earnings of $0.47 per share, which would represent a year-over-year decline of 31.88%.
Investors should also note any recent changes to analyst estimates for BAYRY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 2.05% lower. BAYRY is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, BAYRY is holding a Forward P/E ratio of 8.53. For comparison, its industry has an average Forward P/E of 14.39, which means BAYRY is trading at a discount to the group.
Also, we should mention that BAYRY has a PEG ratio of 0.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BAYRY's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 63, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer (BAYRY) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Bayer (BAYRY - Free Report) closed at $16.36, marking a +0.46% move from the previous day. This move outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the drug and chemical company had lost 4.32% over the past month, lagging the Medical sector's loss of 2.82% and the S&P 500's loss of 0.19% in that time.
Investors will be hoping for strength from BAYRY as it approaches its next earnings release. On that day, BAYRY is projected to report earnings of $0.47 per share, which would represent a year-over-year decline of 31.88%.
Investors should also note any recent changes to analyst estimates for BAYRY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 2.05% lower. BAYRY is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, BAYRY is holding a Forward P/E ratio of 8.53. For comparison, its industry has an average Forward P/E of 14.39, which means BAYRY is trading at a discount to the group.
Also, we should mention that BAYRY has a PEG ratio of 0.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BAYRY's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 63, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.